

Abbratech Inc.  
Financial Conflict of Interest Policy (NIH)  
(Revised 2023-01-12)

**A. Persons covered by this policy**

This policy applies to all personnel, including all Members and full-time, part-time, temporary, and contract employees, of Abbratech, Inc. (“Abbratech”) who are planning to participate in, or are participating in, National Institute of Health (“NIH”) funded research by means of a grant or cooperative agreement.

**B. Preamble**

1. The primary goal of this policy is to promote objectivity in research by establishing standards that provide a reasonable expectation that the design, conduct, and reporting of research funded under NIH grants or cooperative agreements will be free from bias resulting from Investigator financial conflicts of interest and to prevent an employee’s activities from adversely influencing Abbratech operations.
2. It is recognized that research related conflicts of interest can arise from legitimate and appropriate activities including economic development, public-private interactions, and employee’s and their family’s personal business relationships.
3. This policy is implemented in accordance with 42 CFR Part 50 Subpart F - “Responsibility of Applicants for Promoting Objectivity in Research for which Public Health Service Funding is Sought” and 45 CFR Part 94 “Responsible Prospective Contractors” as well as all other relevant policies of federal funding and oversight agencies. Research funded under an SBIR/STTR Phase I is exempt.

**C. Statement of general policy**

1. The design, conduct, and reporting of Research funded under NIH grants or cooperative agreements should be free from bias resulting from Investigator financial conflicts of interest.
2. To provide a reasonable expectation of achieving the goal of this policy, Investigators shall complete appropriate training as required under this policy; Investigators shall disclose perceived and real financial conflicts of interest annually and provide new or updated disclosures in a timely manner; Abbratech shall provide for the elimination or management of Financial Conflicts of Interest; and Abbratech shall make disclosures to both the NIH and to the public as required under this policy.
3. Nothing in this policy shall be construed to permit, even with disclosure, any activity that is prohibited by law.
4. Nothing in this policy shall be construed to limit or abridge the authority of Abbratech Members to take such action as they deem appropriate regardless of any action or inaction by an Officer of Abbratech.

**D. Definitions**

1. *Disclosure* means an Investigator’s disclosure of significant financial interests to Abbratech.

2. *Financial Conflict of Interest (FCOI)* means a Significant Financial Interest that could directly and significantly affect the design, conduct, or reporting of PHS-funded research.
3. *FCOI Report* means Abbratech's report of a Financial Conflict of Interest to a PHS Awarding Component.
4. *Financial Interest* means anything of monetary value, whether or not the value is readily ascertainable.
5. *HHS* means the United States Department of Health and Human Services, and any components of the Department to which the authority involved may be delegated.
6. *Institutional Official (IO)* means a Abbratech-designated official assigned to solicit and review disclosure forms from each investigator who is planning to participate in, or who is participating in, HHS funded research and to determine whether any reported Significant Financial Interest (SFI) is a FCOI.
7. *Company Responsibilities* means an Investigator's professional responsibilities on behalf of Abbratech, and as defined by Abbratech in its policy on financial conflicts of interest, which may include for example: activities such as research, research consultation, training, professional practice, and service on panels.
8. *Investigator* means the project director or principal Investigator and any other person, regardless of title or position, who is responsible for the design, conduct, or reporting of research funded by the PHS, or proposed for such funding, which may include, for example, collaborators, subcontractors, or consultants.
9. *Manage* means taking action to address a financial conflict of interest, which can include reducing or eliminating the financial conflict of interest, to ensure, to the extent possible, that the design, conduct, and reporting of research will be free from bias.
10. *Member* means any person executing the Abbratech Operating Agreement, or thereafter admitted to the Abbratech as a Member as provided in the Abbratech Operating Agreement.
11. *PD/PI* means a project director or principal Investigator of a PHS-funded research project; the PD/PI is included in the definitions of senior/key personnel and Investigator under this subpart.
12. *Research* means a systematic investigation, study or experiment designed to develop or contribute to generalizable knowledge relating broadly to public health. The term encompasses basic and applied research and product development. As used in this subpart, the term includes any such activity for which research funding is available from a NIH through a grant or cooperative agreement, such as a research grant, career development award, center grant, individual fellowship award, infrastructure award, Abbratech training grant, program project, or research resources award.
13. *Senior/key personnel* means the PD/PI and any other person identified as senior/key personnel by Abbratech in the grant application, progress report, or any other report submitted to the PHS by Abbratech under this subpart.
14. *Significant Financial Interest* means the following:
  - a. A Financial Interest consisting of one or more of the following interests of the Investigator (and those of the Investigator's spouse and dependent children)

that reasonably appears to be related to the Investigator's responsibilities at Abbratech:

- i. With regard to any publicly traded entity, a significant financial interest exists if the value of any remuneration received from the entity in the twelve months preceding the disclosure and the value of any equity interest in the entity as of the date of disclosure, when aggregated, exceeds \$5,000. For purposes of this definition, remuneration includes salary and any payment for services not otherwise identified as salary (e.g., consulting fees, honoraria, paid authorship); equity interest includes any stock, stock option, or other ownership interest, as determined through reference to public prices or other reasonable measures of fair market value;
  - ii. With regard to any non-publicly traded entity, a significant financial interest exists if the value of any remuneration received from the entity in the twelve months preceding the disclosure, when aggregated, exceeds \$5,000, or when the Investigator (or the Investigator's spouse or dependent children) holds any equity interest (e.g., stock, stock option, or other ownership interest), or a management or governance position; or
  - iii. Intellectual property rights and interests (e.g., patents, copyrights), upon receipt of income related to such rights and interests.
- b. Travel:
- i. Investigators also must disclose the occurrence of any reimbursed or sponsored travel (i.e., that which is paid on behalf of the Investigator and not reimbursed to the Investigator so that the exact monetary value may not be readily available), related to their Company responsibilities;
  - ii. provided, however, that this disclosure requirement does not apply to travel that is reimbursed or sponsored by a Federal, state, or local government agency, an Institute of higher education as defined at 20 U.S.C. 1001(a), an academic teaching hospital, a medical center, or a research institute that is affiliated with an Institute of higher education.
  - iii. Disclosure for travel shall include, at a minimum, the purpose of the trip, the identity of the sponsor/organizer, the destination, and the duration. Abbratech will determine if further information is needed, including a determination or disclosure of monetary value, in order to determine whether the travel constitutes an FCOI with the PHSfunded research.
- c. Exclusions: The term Significant Financial Interest does not include the following types of financial interests:
- i. salary, royalties, or other remuneration paid by Abbratech to the Investigator if the Investigator is currently employed or otherwise appointed by Abbratech, including intellectual property rights assigned to Abbratech and agreements to share in royalties related to such rights;

- ii. income from investment vehicles, such as mutual funds and retirement accounts, as long as the Investigator does not directly control the investment decisions made in these vehicles;
- iii. income from seminars, lectures, or teaching engagements sponsored by a Federal, state, or local government agency, an Institute of higher education as defined at 20 U.S.C. 1001(a), an academic teaching hospital, a medical center, or a research institute that is affiliated with an Institute of higher education; or
- iv. income from service on advisory committees or review panels for a Federal, state, or local government agency, an Institute of higher education as defined at 20 U.S.C. 1001(a), an academic teaching hospital, a medical center, or a research institute that is affiliated with an Institute of higher education.

#### **E. Policy Implementation**

1. Review Requirement: Abbratech has designated its Managing Partner as the IO. Prior to expenditure of any funds under a HHS funded research project, Abbratech's IO will solicit and review Investigator's disclosures (or Disclosure Forms) containing SFI's to determine whether the SFI relates to the HHS funded Research and whether a FCOI exists.
2. If a FCOI exists, Abbratech's IO will develop and implement a management plan that specifies the actions that have been and will be taken to manage such FCOI.
3. Disclosure Requirement: Abbratech will inform each employee of Abbratech's policy on Promoting Objectivity in Research, the investigator's responsibilities regarding disclosure require that a written disclosure be made as provided in this policy, and inform the Abbratech Member to anticipate the receipt of a new Disclosure.
4. Disclosure Frequency:
  - a. Disclosure must be made no later than at the time of application for NIH-funded research.
  - b. Disclosure must be made annually to Abbratech. If no Significant Financial Interest is present a Disclosure must still be submitted that states "none". The date such annual Disclosure is due shall be set by the Members and disseminated Abbratech-wide.
  - c. In addition to the annual Disclosure, a new or updated Disclosure must be completed in a timely manner whenever a new or potential Significant Financial Interest arises or when a significant change occurs concerning an existing Disclosure.
  - d. In any event, Disclosure must be made within thirty (30) days of discovery or acquiring a new Significant Financial Interest.
  - e. Newly hired Investigators should make a Disclosure as part of their new hire employment process.
5. Training Required: Investigators shall complete FCOI training provided by Abbratech on or before their becoming subject to this policy and then every four (4) years thereafter. Training will include information on Abbratech's policy, Investigator's

disclosure responsibilities, and the Federal regulation. Immediate training will be required if Abbratech revises this policy in a manner that affects the Investigator, when an Investigator is new to Abbratech, or as a result of a finding of noncompliance with this policy or a management plan, or other related misconduct. Training provided via: [https://grants.nih.gov/grants/policy/coi/tutorial2018/story\\_html5.html](https://grants.nih.gov/grants/policy/coi/tutorial2018/story_html5.html)

6. Posting Requirement: If the IO determines FCOI exists prior to Abbratech's expenditure of HHS funds and within sixty (60) days of Brio's receipt or identification of any additional SFI held by Senior/Key personnel performing services for the Research, related to the HHS funded Research and that is determined by Abbratech's IO to be a FCOI, Abbratech shall post to its publicly accessible website, [www.Abbratech.com](http://www.Abbratech.com), the following information concerning such SFI:
  - a. investigator's name, title, and role with respect to the Research project;
  - b. the name of the entity in which the SFI is held;
  - c. the nature of the SFI; and
  - d. approximate dollar value of the SFI (dollar ranges are permissible: \$0 - \$4,999; \$5,000-\$9,999; \$10,000-\$19,000; amounts between \$20,000-\$100,000 by increments of \$20,000; amounts above \$100,000 by increments of \$50,000, or
  - e. a statement that the interest is one whose value cannot be readily determined through reference to public prices or other reasonable measure of fair market value.
7. Management of FCOIs: Examples of conditions or restrictions to include in plans management can be:
  - a. Public disclosure of FCOI (e.g., when presenting or publishing the research);
  - b. For research projects involving human subjects research, disclosure of FCOI directly to participants;
  - c. Appointment of an independent monitor capable of taking measures to protect the design, conduct and reporting of the research against bias resulting from the FCOI
  - d. Modification of the research plan
  - e. Change of personnel or personnel responsibilities, or disqualification of personnel from participation in all or a portion of the research;
  - f. Reduction or elimination of the financial interest (e.g., sale of equity interest); or
  - g. Severance of relationships that create financial conflicts.

## **F. Violations and Sanctions**

1. Sanctions: Violations of Abbratech policies, including the failure to avoid a prohibited activity or disclose a Significant Financial Interest in a timely manner, will be dealt with in accordance with applicable policies and procedures that may include disciplinary actions up to and including termination of employment.
2. Clinical Research: In any case in which the HHS determines that a NIH-funded project of clinical research whose purpose is to evaluate the safety or effectiveness of a drug, medical device, or treatment has been designed, conducted, or reported by an Investigator with a FCOI that was not managed or reported by the Abbratech as required by this policy, the Members shall require the Investigator involved to disclose

the FCOI in each public presentation of the results of the research and to request an addendum to previously published presentations.

### **G. Company Reporting**

1. Abbratech, through its Members shall provide annual and revised reports of FCOI to National Institutes of Health (NIH) per the applicable regulations:
  - a. Prior to the expenditure of funds;
  - b. within sixty days of identification for an Investigator who is newly participating in the project;
  - c. within sixty days for new or newly identified FCOIs for existing investigators
  - d. at least annually (at the same time as when Abbratech is required to submit the annual progress report, multi-year progress report, if applicable, or at time of extension) to provide the status of the FCOI and any changes to the management plan, if applicable, until the completion of the project;
  - e. following retrospective review to update a previously submitted report, if appropriate.
2. Abbratech, through its Members, shall notify NIH of bias found in the design, conduct, or reporting of NIH funded Research including whether Investigator failure to comply with this FCOI policy or management plan appears to have caused such bias. In the event bias is found, Abbratech will submit a Mitigation report in accordance with the regulation. The mitigation report must include, at a minimum, a description of the impact of the bias on the research project and Abbratech's plan of action or actions taken to eliminate or mitigate the effect of the bias (e.g., impact on the research project; extent of harm done, including any qualitative and quantitative data to support any actual or future harm; analysis of whether the research project is salvageable).
3. FCOI records shall be maintained for at least three (3) years from the submission of the final expenditure reports for the pertinent NIH funding or longer as required by other policy or regulation.

### **H. Retrospective Review and Mitigation Report**

If a financial Conflict of Interest is not identified or managed in a timely manner, including:

- Failure by the Investigator to disclose a Significant Financial Interest that is determined by the Institution to constitute a Financial Conflict of Interest;
- Failure by the Institution to review or manage such a Financial Conflict of Interest;
- or
- Failure by the Investigator to comply with a Financial Conflict of Interest management plan; the Institution shall, within 120 days of the Institution's determination of noncompliance, complete a "**retrospective review**" of the Investigator's activities and the NIH-funded research project to determine whether any NIH-funded research, or portion thereof, conducted during the time period of the noncompliance was biased in the design, conduct, or reporting of such research.

The Institution shall document the “**retrospective review**” which must include at least the following key elements:

- Project number;
- Project title;
- PD/PI or contact PD/PI if a multiple PD/PI model is used;
- Name of the Investigator with the FCOI;
- Name of the entity with which the Investigator has a financial conflict of interest
- Reason(s) for the retrospective review;
- Detailed methodology used for the retrospective review (e.g., methodology of the review process, composition of the review panel, documents reviewed, etc.);
- Findings of the review; and Conclusions of the review.

**I. Subrecipients:**

Abbratech, through its Members, shall require sub-recipient compliance with pertinent FCOI requirements as mandated by PHS regulation:

1. If applicable, obtain a certification from the subrecipient that its FCOI policy complies with the regulation.
2. If applicable, include in the written subrecipient agreement a requirement for the subrecipient to report identified FCOIs for its Investigators in a time frame that allows Abbratech to report identified FCOIs to NIH as required by the regulation.
3. Alternatively, if applicable, include in the written agreement a requirement to solicit and review subrecipient Investigator disclosures that enable Abbratech to identify, manage, and report identified FCOIs to NIH.

**J. Public Accessibility Requirement**

1. Abbratech shall post this FCOI policy on Abbratech public website, as required by the regulation.
2. FCOI Informational requests by the public concerning identified FCOIs held by senior/key personnel should be made to the President. The President shall respond to requests for FCOI information within five (5) business days with minimum reporting elements as provided for under applicable regulations.